Communication

Can Immobilized Artificial Membrane Chromatography Support the Characterization of Antimicrobial Peptide Origin Derivatives?

Krzesimir Ciura 1,2,*, Natalia Ptaszyńska 3, Hanna Kapica 1, Monika Pastewska 1, Anna Łęgowska 3, Krzysztof Rolka 3, Wojciech Kamysz 4, Wiesław Sawicki 1 and Katarzyna E. Greber 1,∗

1 Department of Physical Chemistry, Medical University of Gdańsk, Al. Gen. Hallera 107, 80-416 Gdańsk, Poland; hanna.kapica@gumed.edu.pl (H.K.); monika.pastewska@gumed.edu.pl (M.P.); wsawicki@gumed.edu.pl (W.S.)
2 QSAR Lab Ltd., Trzy Lipy 3 St., 80-172 Gdańsk, Poland
3 Department of Molecular Biochemistry, Faculty of Chemistry, University of Gdańsk, 80-308 Gdańsk, Poland; natalia.ptaszynska@ug.edu.pl (N.P.); anna.legowska@ug.edu.pl (A.L.); krzysztof.rolka@ug.edu.pl (K.R.)
4 Department of Inorganic Chemistry, Medical University of Gdańsk, Al. Gen. Hallera 107, 80-416 Gdańsk, Poland; Wojciech.kamysz@gumed.edu.pl
* Correspondence: k.ciura@qsarl.com (K.C.); katarzyna.greber@gumed.edu.pl (K.E.G.)

Abstract: The emergence and spread of multiple drug-resistant bacteria strains caused the development of new antibiotics to be one of the most important challenges of medicinal chemistry. Despite many efforts, the commercial availability of peptide-based antimicrobials is still limited. The presented study aims to explain that immobilized artificial membrane chromatography can support the characterization of antimicrobial peptides. Consequently, the chromatographic experiments of three groups of related peptide substances: (i) short cationic lipopeptides, (ii) citropin analogs, and (iii) conjugates of ciprofloxacin and levofloxacin, with a cell-penetrating peptide were discussed. In light of the discussion of the mechanisms of action of these compounds, the obtained results were interpreted.

Keywords: IAM-HPLC; antimicrobial peptide; cell-penetrating peptide (CPP); transportan 10 (TP10-NH2); short cationic lipopeptides

1. Introduction

The development of new antimicrobial agents is one of the most critical challenges of medicinal chemistry. Several natural and synthetic compounds have been explored and investigated to find new, effective, and safe antimicrobial agents. The antimicrobial peptides, lipopeptides, and other peptide origin derivatives, such as peptidomimetics, are very promising structures among the tested substances. They showed severe therapeutic potential due to their broad spectrum of activity, rapid bacterial killing, and synergy with classical antibiotics [1–3]. Generally, the antibacterial mechanism of action of peptides and lipopeptides is mainly connected with the interactions between peptides and bacterial membranes [4], but some studies showed different results [5]. Nonetheless, the most recognized mechanisms of action are the barrel-stave model, carpet model, and toroidal model for killing pathogenic bacteria organisms [6].

Understanding the physicochemical and structural properties of peptides is an essential requisite for the rational design of active derivatives. Nevertheless, their lipophilicity is challenging to analyze using traditional in silico or octanol/water partition coefficients. Consequently, the estimation of their in vivo distribution and permeability is also...
difficult [7]. Except for family cell-penetrating peptides (CPP) [8], their peptide derivatives also often showed limited cell permeability due to their polar nature. For this reason, the assessment of phospholipid’s affinity for peptide derivatives is critical. Generally, the partitioning systems containing phospholipids as the organic phase, like liposomes or cell culture techniques, can mimic the interactions between peptides and biological membranes [9].

Nevertheless, nowadays, the most popular approach involves immobilized artificial membrane HPLC (IAM-HPLC). Several advantages of IAM-HPLC include complete automation, a short analysis time, and excellent lab-to-lab reproducibility. What is more, Valko and coworkers reported promising results of an phospholipid-binding study of potential peptide therapeutics using IAM-HPLC [10–16].

This study continues our research program focused on assessing the physicochemical properties of drug candidates using chromatographic and biochromatographic approaches [17–24]. In this study, we investigated the possibility of using IAM-HPLC for the characterization of three groups of related peptide substances: (i) short cationic lipopeptides, (ii) citropin analogs, and (iii) conjugates of ciprofloxacin (CIP) and levofloxacin (LVX) with a cell-penetrating peptide named transoprtan 10 (TP10-NH2) and its analog extended at N-terminus by L-cysteine synthesized in our and collaborated laboratories.

2. Results

In Table 1, the experimentally determined time of retention in the investigated IAM-HPLC system and calculated using calibration cure chromatographic hydrophobicity indices of IAM (CHI\textsubscript{IAM}) was noticed. In short, cationic lipopeptides have strong interactions between the stationary phase and analytes occurring and do not migrate. The conjugates of ciprofloxacin and levofloxacin with a cell-penetrating peptide behaved completely contrary. All target derivatives (six conjugates of CIP and LVX with TP10-NH2) migrated to the front of the mobile phase. The retention time of the citropin analogs ranged from 3.349 to 4.495 min, which referred to 27.85–45.95 CHI\textsubscript{IAM}, respectively.

| Analyte     | TR1 | TR2 | TR3 | Mean TR | CHI\textsubscript{IAM} |
|-------------|-----|-----|-----|---------|------------------------|
| (4–16) Citropin | 3.987 | 3.979 | 3.985 | 3.984 | 38.24 |
| (8–16) Citropin | 4.482 | 4.496 | 4.506 | 4.495 | 45.95 |
| (1–7) Citropin | 4.240 | 4.244 | 4.244 | 4.243 | 42.15 |
| (4–14) Citropin | 3.305 | 3.289 | 3.293 | 3.295 | 27.85 |
| (1–7)–(10–16) Citropin | 3.888 | 3.901 | 3.934 | 3.908 | 37.09 |
| (1–5)–(12–16) Citropin | 3.349 | 3.348 | 3.351 | 3.349 | 28.66 |
| Levofloxacin | 3.087 | 3.089 | 3.101 | 3.092 | 24.88 |
| Ciprofloxacin | 2.886 | 2.921 | 2.899 | 2.902 | 19.70 |

3. Discussion

Several pharmaceutical and biotechnological companies are currently looking for new modalities outside the traditional small molecular drug space [7]. However, the obtained results seem to look disappointing, as typical negative experiments since the quantitative data were obtained for only one series of the tested compounds. It could be beneficial to understand the possible mechanisms of action better. In the case of short cationic lipopeptides, there are probably occurring simultaneous hydrophobic interactions between the hydrocarbon chains and interactions between the positively charged amino acid head and the negatively charged phosphate group present in the structure of phosphatidylcholine. The combination of these interactions causes very strong interactions with the phospholipids. Interestingly, both active and nonactive substances can not be eluted from IAM only using the 100% organic phase [5,25]. This finding suggested that the mechanism
of action of short cationic lipopeptides is not trivial and meets our earlier results as to its more complex nature than just the simple surfactant [5,25]. An interesting situation was observed in the case of the conjugates of CIP and LVX with transportan 10. The parent fluoroquinolone antibiotics showed a moderate affinity to the phospholipids: 24.88 and 19.70 CHIIAM for LVX and CIP. However, when covalently linked with TP10-NH₂, they lost their affinity to the phospholipids. At the same time, the synthesized conjugates remained highly biologically active [26]. It is worth highlighting that fluoroquinolone antibiotics may also penetrate bacterial cells in a hydrophilic way using porin channels [27,28]. The latter can explain the visible activity of the tested conjugates. This assumption is supported by the observation of improved dissolution in the water of the designed conjugates compared to the started fluoroquinolone antibiotics structures. Among the tested substances, citropin analogs characterized a moderate to relatively high affinity to stationary IAM. These results indicated that the citropin derivatives should penetrate the biological membranes.

4. Materials and Methods

4.1. Materials and Analytes

4.1.1. Short Cationic Lipopeptides

The lipopeptides sequences were de novo designed and synthesized using the 9-fluorenylmethoxycarbonyl (Fmoc) methodology on the Fmoc-Rink Amide AM resin (0.59 mmol/g, IrisBiotech, Marktredwitz, Germany) [29]. To remove the Fmoc group from the protected amino acid residue, a 20% solution of piperidine in N,N-dimethyloformamide (DMF) was used. A peptide bond was created by in situ activation with the diizopropylcarbodimide/1-hydroxybenzotriazole (DIC/HOBT) procedure. Deanchoring of the lipopeptides from the solid support and deprotection of the amino acid side chains were achieved by treating the lipopeptidyl resin with the mixture of trifluoroacetic acid (TFA; 95%), triizopropylosilane (TIS; 2.5%), and water (2.5%) for 1 h. The deanchoring mixture was then drained, concentrated on a rotary evaporator (Heidolph, Schwabach, Germany), and treated with cold diethyl ether to precipitate the lipopeptides. The precipitated lipopeptides were dissolved in water and freeze-dried (Christ, Martinsried, Germany).

Purification of the synthesized lipopeptides was carried out by semipreparative reverse-phase high-performance liquid chromatography (RP-HPLC) on a C8e column (Macherey-Nagel, Düren, Germany) with a linear gradient (20–60%) of acetonitrile in water (both solvents contained 0.1% TFA). The identity of the obtained lipopeptides was confirmed via mass spectrometry (MALDI-TOF, Bruker Daltonics, Ettlingen, Germany). The sequences of the target antimicrobial lipopeptides are presented in Table 2.

**Table 2.** Amino acid sequences of the studied antimicrobial lipopeptides.

| Double Fatty Acid Chain Lipopeptides | Tetradecanoic Fatty Acid Lipopeptides | Hexadecanoic Fatty Acid Lipopeptides |
|-------------------------------------|--------------------------------------|-------------------------------------|
| (C₈)₂KKKK-NH₂                        | C₁₄-K-NH₂                            | C₁₆-K-NH₂                            |
| (C₁₀)₂KKKK-NH₂                        | C₁₆-KG-NH₂                            | C₁₆-KGK-NH₂                           |
| (C₁₂)₂KKKK-NH₂                        | C₁₆-KKG-NH₂                           | C₁₆-KKGK-NH₂                          |
| (C₁₄)₂KKKK-NH₂                        | C₁₆-KGG-NH₂                           | C₁₆-KKK-NH₂                           |
| (C₁₆)₂KKKK-NH₂                        | C₁₆-KKKK-NH₂                          | C₁₆-KKKY-NH₂                          |
| (C₁₆)₂KKKK-NH₂                        | C₁₆-KKKKK-NH₂                         | C₁₆-KKS-NH₂                           |
4.1.2. Citropin Analogs

The citropin analogs were assembled manually by solid-phase procedures on a polystyrene AM-RAM resin (0.66 mmol/g, Rapp Polymere, Tuebingen, Germany) using 9-fluorenylmethoxycarbonyl (Fmoc) methodology [29].

The Fmoc group was removed from the protected amino acid residue by a 20% solution of piperidine in N,N-dimethylformamide (DMF). A peptide bond was created by the in situ activation with the 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyllumonium hexafluorophosphate/N,N-diisopropylethyamine (HTBU/DIPEA) procedure. Deanchoring of the peptides from the solid support and deprotection of the amino acid side chains were achieved by treating the peptidyl resin with the mixture of trifluoroacetic acid (TFA; 95%), trizopropylsilane (TIS; 2.5%), and water (2.5%) for 2 h. The deanchoring mixture was then drained, concentrated on a rotary evaporator (Heidolph, Schwabach, Germany), and treated with cold diethyl ether to precipitate the peptides. The precipitated peptides were dissolved in 2% ACN and freeze-dried (Christ, Martinsried, Germany).

Purification of the synthesized peptides was carried out by semipreparative reverse-phase high-performance liquid chromatography (RP-HPLC) on a C18e column (Macharey-Nagel, Düren, Germany) with a linear gradient (20–40%) of acetonitrile in water (both solvents contained 0.1% TFA). Each citropin analog was analyzed by RP-HPLC and matrix-assisted laser-desorption ionization time-of-flight mass spectrometry MALDI-TOF (Bruker Daltonics, Ettlingen, Germany). The sequences of the investigated citropin analogs are presented in Table 3.

| Antimicrobial Peptides | Amino Acid Sequences |
|------------------------|----------------------|
| Citropin 1.1            | GLFDVIKKVASVIGGL-NH₂ |
| (4–16) Citropin         | DVIKKVASVIGGL-NH₂    |
| (8–16) Citropin         | KVASVIGGL-NH₂        |
| (1–7) Citropin          | GLFDVIK-NH₂          |
| (4–14) Citropin         | DVIKKVASVIG-NH₂      |
| (1–7)–(10–16) Citropin  | GLFDVIKASVIGGL-NH₂   |
| (1–5)–(12–16) Citropin  | GLFDVVGGL-NH₂        |

4.1.3. Conjugates of Ciprofloxacin (CIP) and Levofloxacin (LVX) with a Cell-Penetrating Peptide

TP10-NH₂ and CTP10-NH₂ were obtained using the standard Fmoc chemistry solid-phase peptide synthesis (SPPS) utilizing an automatic Prelude peptide synthesizer (Gyros Protein Technology Inc., Tucson, AZ, USA) and have been described previously [26]. The peptides were synthesized on a TentaGel S RAM resin (substitution 0.24 meq/g, Rapp Polymere, Germany) to obtain peptides with an amide group on the C-terminus after cleavage. After completing the synthesis, the peptides were removed from the resin in a one-step procedure using a mixture of TFA:phenol:trizopropylsilane:H₂O (88:5:2.5, v/v/v/v). The obtained peptides were purified using PLC 2050 Gilson HPLC with Gilson Glider Prep. software (Gilson, Villiers le bel, France). The device was provided with a Grace Vydac C18 (218TP) HPLC column (22 mm × 250 mm, 10 μm, 300 Å, Resolution Systems). The solvent systems were 0.1% TFA in water (A) and 80% acetonitrile in A (B). Different linear gradients were applied (flow rate 20 mL min⁻¹ monitored at 226 nm). The homogeneity of the compounds was examined with the HPLC Pro Star system (Varian, Mulgrave, Australia) and using a Kinetex 5-μm XB-C18 100 Å column (4.6 mm × 150 mm, Phenomenex®, Torrance, CA, USA). A linear gradient from 10 to 90% B for 40 min with a flow rate of 1 mL min⁻¹ monitored at 226 nm was utilized. The synthesized peptides had a purity of at least 95%. The correctness of the molecular masses of the synthesized compounds was confirmed by a mass spectrometry analysis using MALDI-TOF MS (Biflex III MALDI-TOF spectrometer, Bruker Daltonics, Ettlingen, Germany or MALDI TOF/TOF
5800+ spectrometer, AB SCIEX, Framingham, Massachusetts, USA), with an α-cyano-4-
hydroxycinnamic acid (CCA) and/or 2,5-dihydroxybenzoic acid (DHB) matrix.

All conjugates were synthesized according to the methodology described previously [26,30]. In the case of conjugates 2 and 4, CIP and LVX were manually added to the peptidyl resin. N,N'-disopropylcarbodiimide (DIC), N,N'-diisopropylethylamine, and LVX or Boc-CIP (3 equiv. of each) were dissolved in an equimolar amount of DMF/DCM, put in the SPPS vessel with the peptidyl resin, and mixed for 90 min. This procedure was repeated until the chloranil test gave a negative result. To synthesize conjugate 2, the sub-
monomeric approach [30] was utilized. In the first step, bromoacetic acid and DIC (5 equiv. of each) in DCM/DMF (1/1; v/v) were added to the peptidyl resin and stirred in the SPPS vessel for 30 min. This procedure was repeated twice. The coupling of ciprofloxacin to the peptidyl resin was achieved by adding a suspension of CIP (1.5 equiv.) and triethyl-
amine (1.5 equiv.) in DCM/DMF. The coupling reaction took 24 h at room temperature. Conjugate 3 was obtained in a two-step procedure. Firstly, Lomant’s reagent (DSP) (1.2 equiv.) was dissolved in DMF, added to the SPPS vessel with the peptidyl resin, and shaken 24 h. This procedure was repeated twice. In the next step, ciprofloxacin and triethyl-
amine (1.5 equiv. each) were dissolved in an equimolar amount of DMF/DCM and added to the peptidyl resin with an attached DSP. The coupling took another 24 h at room temperature. Finally, all the conjugates were cleaved from the resin and purified as described before. In order to obtain conjugates 5 and 6, the disulfide bridge formation be-
tween LVX and CIP and CTP10-NH2 was preceded by the coupling of the antibiotic to the Cys derivative. To obtain conjugate 5, LVX-Cys (Npys) (12 mg, 0.02 mmol) was dissolved in 5 mL of DMF, and CTP10-NH2 (46 mg, 0.02 mmol) was added, and the reaction was mixed for 4 h at room temperature. The progress of the reaction was examined by analytical HPLC. After 4 h, the solvent was removed in vacuo, and the conjugate was purified by semipreparative HPLC. In the case of conjugate 6, the disulfide bridge was formed during the reaction of CTP10-NH2 and Cys(Npys)-CIP, as described above for 5. In Figure 1, the structures of the CIP and LVX conjugates are presented.

PEPTIDE CONJUGATES

![Chemical structures of the CIP and LVX conjugates with transportan 10 and their constituents [26].](image-url)

Figure 1. Chemical structures of the CIP and LVX conjugates with transportan 10 and their constituents [26].
4.2. HPLC Analysis

All HPLC experiments were carried out using a Prominence-1 LC-2030C 3D HPLC system (Shimadzu, Tokyo, Japan) equipped with an IAM.PC.DD2 column (10 mm × 4.6 mm; particle size 10.0 μm with an IAM guard column; Regis Technologies, Austin Ave, Morton Grove, USA) and diode array detection (DAD). The HPLC system was controlled by LabSolution software (version 5.90, Shimadzu, Japan). The stock solutions of the solutes were diluted to obtain 100-μg/mL concentrations, and the injected volume was 10 μL, which was used for the analytes. The IAM-HPLC analyses were performed with a linear gradient of 0–85% in phase B (where phase A was 10-mM phosphoric buffer at pH 7.4, and phase B was acetonitrile) at a flow rate of 1.5 mL/min. The ultrapure water used for the mobile phase preparation was purified by the Millipore Direct-Q 3 UVWater Purification System (Millipore Corporation, Bedford, MA, USA). The other reagents used for the preparation of the mobile phase: acetonitrile, sodium phosphate dibasic dehydrate, and sodium phosphate monobasic monohydrate (Sigma-Aldrich, Steinheim, Germany) were analytical grade. During the chromatographic analysis, the temperature of the column was constant at 30.0 °C, and the analysis time was 6.5 min. The CHIAM indices of the target solutes were obtained using a calibration set of the reference substances using the protocol developed by Valko and coworkers [13,14]. The reference substances were purchased, respectively: octanonophenone and butyrophenone acetanilide (Alfa Aesar, Haverhill, MA, USA); acetaminophen, acetophenone, levofloxacin, and ciprofloxacin (Sigma-Aldrich, Steinheim, Germany); and heptanophenone, hexanophenone, valerophenone, propiophenone, and acetophenone (Acros Organic, Pittsburg, PA, USA). Figure 2 presents a correlations plot of the CHIAM indices of the model substances and experimentally determined retention times.

![Figure 2. Calibration curve of the IAM-HPLC: acetaminophen (tR 1.93, CHIAM 2.90), acetonilidine (tR 2.37, CHIAM 11.50), acetable (tR 2.66, CHIAM 17.20), propiophenone (tR 3.22, CHIAM 25.90), butyrophenone (tR 3.67, CHIAM 32.00), valerophenone (tR 4.04, CHIAM 37.30), hexanophenone (tR 4.35, CHIAM 41.80), heptanophenone (tR 4.61 CHIAM 45.70), and octanophenone (tR 4.83, CHIAM 49.4).](image)

5. Conclusions

IAM-HPLC may be a valuable tool for the characterization of antimicrobial peptide origin derivatives. Although, in the case of short cationic lipopeptides and conjugates of CIP and LVX with TP10-NH₂, the results only have a qualitative nature, they can broaden the inference about their mechanisms of action. Nevertheless, the obtained results should be applied with care, since the surface of the IAM phase only simplifies the nature of the cell membrane. From a practical point of view, another critical observation is that a strong
interaction between short cationic lipopeptides and the IAM stationary phase can be utilized to develop an effective method for their purification. Furthermore, IAM-HPLC can be used for the rapid screening of the physicochemical properties of citropin analogs. In the case of this class of chemical structures, it could be recommended as a screening method for the further optimization of citropin derivatives.

**Author Contributions:** Conceptualization: K.C., N.P., and K.E.G.; Methodology: K.C.; Software: K.C.; Formal analysis: K.C.; Investigation: H.K. and M.P.; Resources: K.E.G.; W.K.; N.P.; K.R., and A.L.; Data curation: K.C.; Writing—original draft preparation: K.C.; Writing—review and editing: K.C. and N.P.; Visualization: K.C.; Supervision: K.C.; W.S., and K.R.; Project administration: K.C.; and Funding acquisition: K.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Ministry of Science and Higher Education by means of the ST3 02-0003/07/518 statutory funds and the National Centre for Research and Development under grant agreement PeptAlm.

**Data Availability Statement:** All data are presented in Table 1.

**Conflicts of Interest:** The authors declare no conflicts of interest.

**References**

1. Huan, Y.; Kong, Q.; Mou, H.; Yi, H. Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. *Front. Microbiol.* **2020**, *11*, 2559, doi:10.3389/fmicb.2020.582779.

2. Mahlapuu, M.; Håkansson, J.; Ringstad, L.; Björn, C. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. *Front. Cell. Infect. Microbiol.* **2016**, *6*, 194, doi:10.3389/fcimb.2016.00194.

3. Hancock, R.E.; Chapple, D.S. Peptide antibiotics. *Antimicrob. Agents Chemother.* **1999**, *43*, 1317–1323, doi:10.1128/AAC.43.6.1317.

4. Colomb-Cotinat, M.; Lacoste, J.; Brun-Buisson, C.; Jarlier, V.; Coignard, B.; Vaux, S. Estimating the morbidity and mortality associated with infections due to multidrug-resistant bacteria (MDRB), France, 2012. *Antimicrob. Resist. Infect. Control* **2016**, *5*, 56, doi:10.1186/s13756-016-0154-z.

5. Greber, K.E.; Zieleńska, J.; Nierzwicki, L.; Ciura, K.; Kawczak, P.; Nowakowska, J.; Bączek, T.; Sawicki, W. Are the short cationic lipopeptides bacterial membrane disruptors? Structure-Activity Relationship and molecular dynamic evaluation. *Biochim. Biophys. Acta - Biomembr.* **2019**, *1861*, doi:10.1016/j.bbamem.2018.08.013.

6. Khurshid, Z.; Naseem, M.; Sheikh, Z.; Najeeb, S.; Shahab, S.; Zafar, M.S. Oral antimicrobial peptides: Types and role in the oral cavity. *Saudi Pharm. J.* **2016**, *24*, 514–524, doi:10.1016/j.sjps.2015.02.015.

7. Valko, K.; Ivanova-Berndt, G.; Beswick, P.; Kindey, M.; Ko, D. Application of biomimetic HPLC to estimate lipophilicity, protein and phospholipid binding of potential peptide therapeutics. *ADMET DMPK* **2018**, *6*, 162–175, doi:10.5599/admet.544.

8. Vivès, E.; Schmidt, J.; Pêlegrin, A. Cell-penetrating and cell-targeting peptides in drug delivery. *Biochim. Biophys. Acta - Rev. Cancer* **2008**, *1786*, 126–138, doi:https://doi.org/10.1016/j.bbcan.2008.03.001.

9. Loureiro, D.R.P.; Soares, J.X.; Lopes, D.; Macedo, T.; Yordanova, D.; Jakobtorweihen, S.; Nunes, C.; Reis, S.; Pinto, M.M.M.; Afonso, C.M.M. Accessing lipophilicity of drugs with biomimetic models: A comparative study using liposomes and micelles. *Eur. J. Pharm. Sci.* **2018**, *115*, 369–380, doi:https://doi.org/10.1016/j.ejps.2018.01.029.

10. Grumetto, L.; Russo, G.; Barbato, F. Relationships between human intestinal absorption and polar interactions drug/phospholipids estimated by IAM-HPLC. *Int. J. Pharm.* **2015**, *489*, 186–194, doi:10.1016/j.ijpharm.2015.04.062.

11. Russo, G.; Grumetto, L.; Barbato, F.; Vistoli, G.; Pedretti, A. Prediction and mechanism elucidation of analyte retention on phospholipid stationary phases (IAM-HPLC) by in silico calculated physico-chemical descriptors. *Eur. J. Pharm. Sci.* **2017**, *99*, 173–184, doi:10.1016/j.ejps.2016.11.026.

12. Grumetto, L.; Russo, G.; Barbato, F. Immobilized Artificial Membrane HPLC Derived Parameters vs PAMPA-BBB Data in Estimating In Situ Measured Blood-Brain Barrier Permeation of Drugs. *Mol. Pharm.* **2016**, *13*, 2808–2816, doi:10.1021/acs.molpharmaceut.6b00397.

13. Valko, K.; Du, C.M.; Bevan, C.D.; Reynolds, D.P.; Abraham, M.H. Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: Comparison with other lipophilicity measures. *J. Pharm. Sci.* **2000**, *89*, 1085–1096, doi:10.1002/1520-6178(200008)89:8<1085::AID-JPS13>3.0.CO;2-N.

14. Valkó, K.L. Lipophilicity and biomimetic properties measured by HPLC to support drug discovery. *J. Pharm. Biomed. Anal.* **2016**, *130*, 35–54, doi:10.1016/j.jpba.2016.04.009.

15. Valko, K.L. Chromatographic technique to support ADMET&DMPK in early drug discovery. *ADMET DMPK* **2018**, *6*, 71, doi:10.5599/admet.559.

16. Teague, S.; Valko, K. How to identify and eliminate compounds with a risk of high clinical dose during the early phase of lead optimisation in drug discovery. *Eur. J. Pharm. Sci.* **2017**, *110*, 37–50, doi:https://doi.org/10.1016/j.ejps.2017.02.017.
17. Ciura, K.; Pastewska, M.; Ulenberg, S.; Kapica, H.; Kawczak, P.; Bączek, T. Chemometric analysis of bio-inspired micellar electrokinetic chromatographic systems – modelling of retention mechanism and prediction of biological properties using bile salts surfactants. Microchem. J. 2021, 167, doi:10.1016/j.microc.2021.106340.

18. Ciura, K.; Fedorowicz, J.; Sączewski, J.; Kapica, H.; Pastewska, M.; Sawicki, W. Interaction between antifungal isoxazolo[3,4-b]pyridin 3(1H)-one derivatives and human serum proteins analyzed with biomimetic chromatography and qsar approach. Processes 2021, 9, 512, doi:10.3390/pr9030512.

19. Ciura, K.; Kapica, H.; Dziomba, S.; Kawczak, P.; Belka, M.; Bączek, T. Biopartitioning micellar electrokinetic chromatography – Concept study of cationic analytes. Microchem. J. 2020, 154, 104518, doi:10.1016/j.microc.2019.104518.

20. Ciura, K.; Fedorowicz, J.; Kapica, H.; Adamkowska, A.; Sawicki, W.; Szczezewska, J. Affinity of fluorquinolone-safirinium dye hybrids to phospholipids estimated by IAM-HPLC. Processes 2020, 8, 1148, doi:10.3390/pr8091148.

21. Ciura, K.; Fedorowicz, J.; Žuvela, P.; Lovrić, M.; Kapica, H.; Baranowski, P.; Sawicki, W.; Sączewski, J. Affinity of antifungal isoxazolo[3,4-b]pyridine-3(1H)-ones to phospholipids in immobilized artificial membrane (IAM) chromatography. Molecules 2020, 25, 4835, doi:10.3390/molecules25204835.

22. Ciura, K.; Ulenberg, S.; Kapica, H.; Kawczak, P.; Belka, M.; Bączek, T. Drug affinity to human serum albumin prediction by retention of cetyltrimethylammonium bromide pseudostationary phase in micellar electrokinetic chromatography and chemically advanced template search descriptors. J. Pharm. Biomed. Anal. 2020, 188, 113423, doi:10.1016/j.jpba.2020.113423.

23. Ciura, K.; Ulenberg, S.; Kapica, H.; Kawczak, P.; Belka, M.; Bączek, T. Assessment of blood–brain barrier permeability using micellar electrokinetic chromatography and P_VSA-like descriptors. Microchem. J. 2020, 158, 105236, doi:10.1016/j.microc.2020.105236.

24. Pastewska, M.; Bednarczyk-Cwynar, B.; Kovačević, S.; Buławska, N.; Ulenberg, S.; Georgiev, P.; Kapica, H.; Kawczak, P.; Bączek, T.; Sawicki, W.; et al. Multivariate assessment of anticancer oleanane triterpenoids lipophilicity. J. Chromatogr. A 2021, 1656, 462552, doi:10.1016/j.chroma.2021.462552.

25. Greber, K.E.; Ciura, K.; Belka, M.; Kawczak, P.; Nowakowska, J.; Bączek, T.; Sawicki, W. Characterization of antimicrobial and hemolytic properties of short synthetic cationic lipopeptides based on QSAR/QSTR approach. Amino Acids 2018, 50, 479–485, doi:10.1007/s00726-017-2530-2.

26. Ptaszyńska, N.; Gucwa, K.; Olkiewicz, K.; Serocki, M.; Stupak, A.; Martynow, D.; Dębowski, D.; Gitlin-Domagalska, A.; Lica, J.; et al. Conjugates of Ciprofloxacin and Levofloxacin with Cell-Penetrating Peptide Exhibit Antifungal Activity and Mammalian Cytotoxicity. Int. J. Mol. Sci. 2020, 21, 4696, doi:10.3390/ijms21134696.

27. Marshall, A.J.H.; Piddock, L.J.V. Interaction of divalent cations, quinolones and bacteria. J. Antimicrob. Chemother. 1994, 34, 465–483, doi:10.1093/jac/34.4.465.

28. Chapman, J.S.; Georgopapadakou, N.H. Routes of quinolone permeation in Escherichia coli. Antimicrob. Agents Chemother. 1988, 32, 438–442, doi:10.1128/AAC.32.4.438.

29. Fields, G.B.; Noble, R.L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 1990, 35, 161–214, doi:10.1111/j.1399-3011.1990.tb00939.x.

30. Ptaszyńska, N.; Olkiewicz, K.; Okońska, J.; Gucwa, K.; Łęgowska, A.; Gitlin-Domagalska, A.; Dębowski, D.; Lica, J.; Heldt, M.; Milewski, S.; et al. Peptide conjugates of lactoferrin analogues and antimicrobials-Design, chemical synthesis, and evaluation of antimicrobial activity and mammalian cytotoxicity. Peptides 2019, 117, 170079, doi:10.1016/j.peptides.2019.04.006.